Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Recursion Pharmaceuticals, Inc. - Class A Common Stock (NQ:RXRX)

3.105 +0.055 (+1.80%)
Streaming Delayed Price Updated: 12:09 PM EDT, May 14, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Recursion Pharmaceuticals, Inc. - Class A Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
18 19 Next >
News headline image
3 Stocks Poised to Disrupt the Healthcare Market by 2030 ↗
The old healthcare model is breaking down. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Recursion (RXRX) Q1 2026 Earnings Transcript ↗
Recursion (RXRX) Q1 2026 Earnings Transcript 
Via The Motley Fool
Topics Artificial Intelligence
Recursion Pharmaceuticals (RXRX) Q1 2026 Results: Revenue Miss Overshadows Narrower Net Loss ↗
Via Chartmill
News headline image
Lilly’s $47.8 Billion Bet: Why the Contessa Acquisition Redefines the Future of Medicine
In a move that has sent shockwaves through both the pharmaceutical and technology sectors, Eli Lilly and Company (NYSE: LLY) announced today, April 6, 2026, the finalized acquisition of Contessa, a... 
Via MarketMinute
Topics Artificial Intelligence
Recursion Pharmaceuticals (NASDAQ:RXRX) Soars on Q4 Earnings Beat ↗
Via Chartmill
News headline image
1 Beaten-Down AI Stock to Buy and 1 to Avoid ↗
One of these is not like the other. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
2 AI Healthcare Stocks to Buy Right Now ↗
The convergence of two already fantastic industries is creating an incredible opportunity. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Prediction: The "Trough of Disillusionment" Will Create the Best Buying Opportunity for Artificial Intelligence (AI) Stocks in 2026 ↗
The sweeping correction that most of these stocks have suffered was not only predictable, but it also reliably precedes a better-supported recovery. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Want $1 Million in Retirement? Invest $10,000 in These 2 AI Stocks and Hold for 10 Years. ↗
AI is rewriting drug discovery. Recursion Pharmaceuticals and Tempus AI might be the platforms that turn early investors into millionaires. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Can This AI Stock Bounce Back in 2026? ↗
It's not looking too good for the biotech. 
Via The Motley Fool
Topics Animal Testing Artificial Intelligence
News headline image
Recursion (RXRX) Q4 2025 Earnings Call Transcript ↗
Recursion (RXRX) Q4 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Artificial Intelligence Earnings
News headline image
What's Behind The Jump In Recursion Pharmaceuticals Stock? ↗
Shares of Recursion Pharmaceuticals (NASDAQ: RXRX) are surging Wednesday following a robust earnings report released before the bell. 
Via Benzinga
News headline image
RXRX Stock Soars Pre-Market On Q4 Beat, Recursion CEO Says Company Has ‘Reached An Inflection Point’ ↗
Recursion reported a loss of $0.21 per share on revenue of $35.5 million, compared to Wall Street estimates of a loss of $0.32 per share on revenue of $24.6 million, according to Koyfin. 
Via Stocktwits
Topics Artificial Intelligence
News headline image
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought ↗
Ark Invest added to three positions that are well below last year's highs. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
NVIDIA’s 13F Bombshell: A New AI Power Trio Emerges ↗
Via MarketBeat
Topics Artificial Intelligence
News headline image
Recursion Pharmaceuticals Stock Drops: What's Behind It? ↗
Recursion Pharmaceuticals Inc (NASDAQ:RXRX) shares are under pressure Wednesday after new regulatory filings showed that Nvidia Corp (NASDAQ:NVDA) has fully exited its investment in the AI‑focused... 
Via Benzinga
News headline image
The Biotechnology Renaissance: AI and Capital Collide in a Multi-Trillion Dollar Pivot
As of February 17, 2026, the biotechnology sector is undergoing its most significant structural transformation in decades, a period now widely termed the "Biotechnology Renaissance." Following a... 
Via MarketMinute
Topics Artificial Intelligence Economy Initial Public Offering
News headline image
This $4 Stock Could Be Your Ticket to Millionaire Status ↗
It's a potential game-changing technology. The company just needs to prove to the world that it works well enough. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Harvard’s PopEVE AI Cracks the Code of Rare Diseases: Ending the ‘Diagnostic Odyssey’ for Millions
In a landmark achievement for computational biology, researchers from Harvard Medical School and the Centre for Genomic Regulation (CRG) have unveiled PopEVE, a groundbreaking artificial intelligence... 
Via TokenRing AI
Topics Artificial Intelligence
News headline image
AI’s ‘Penicillin Moment’: How Generative Models Are Slashing Decades of Antibiotic Research into Months
In a breakthrough that many are calling the "Penicillin Moment" of the 21st century, researchers at the Massachusetts Institute of Technology, led by bioengineering pioneer James Collins, have... 
Via TokenRing AI
Topics Artificial Intelligence
News headline image
Forget 2025: These 2 Growth Stocks Could Soar in 2026 ↗
Last year's weakness is ultimately an improved entry opportunity for long-term-minded investors. 
Via The Motley Fool
News headline image
Can This Beaten-Down AI Stock Bounce Back in 2026? ↗
It might take a while for this AI company to prove its worth, if it ever does so. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
2 AI Stocks to Buy in 2026, and 1 to Avoid ↗
Some AI-focused companies are not worth the trouble. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Beyond the Protein: How AlphaFold 3 Redefined the Blueprint of Life and Accelerated the Drug Discovery Revolution
In the two years since its unveiling, AlphaFold 3 (AF3) has fundamentally transformed the landscape of biological research, moving the industry from simple protein folding to a comprehensive "all-atom"... 
Via TokenRing AI
Topics Artificial Intelligence
News headline image
From Silicon to Syringes: Nvidia’s AI Dominance Solidified Through Landmark Eli Lilly Alliance
In a move that signals the definitive convergence of high-performance computing and biotechnology, NVIDIA Corporation (NASDAQ: NVDA) and Eli Lilly and Company (NYSE: LLY) announced a massive $1 billion... 
Via MarketMinute
Topics Artificial Intelligence Economy Intellectual Property
News headline image
The $3 Billion Bet: How Isomorphic Labs is Rewriting the Rules of Drug Discovery with Eli Lilly and Novartis
In a move that has fundamentally reshaped the landscape of the pharmaceutical industry, Isomorphic Labs—the London-based drug discovery arm of Alphabet Inc. (NASDAQ: GOOGL)—has solidified its position... 
Via TokenRing AI
Topics Artificial Intelligence
News headline image
The Great Unlocking: How AlphaFold 3’s Open-Source Pivot Sparked a New Era of Drug Discovery
The landscape of biological science underwent a seismic shift in November 2024, when Google DeepMind, a subsidiary of Alphabet Inc. (NASDAQ: GOOGL), officially released the source code and model... 
Via TokenRing AI
Topics Artificial Intelligence
News headline image
Forget Recursion Pharmaceuticals Stock. This Is a Much Better Buy. ↗
These two companies have very different risk-reward profiles. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Cathie Wood’s Strategic Pivot: Ark Invest Trims Tesla Holdings to Fuel AI and Crypto Bets Ahead of 2026
In a move that has captured the attention of Wall Street as the year draws to a close, Cathie Wood’s Ark Invest has executed a series of significant sales of Tesla, Inc. (NASDAQ: TSLA) stock throughout... 
Via MarketMinute
Topics Artificial Intelligence ETFs Economy
Why Recursion Pharmaceuticals Stock Vaulted 11% Higher on Wednesday ↗
Sentiment on the company has improved following solid clinical trial results from one of its pipeline drugs earlier this month. 
Via The Motley Fool
Topics Artificial Intelligence
< Previous 1 2 3 4 5 6 7 8 9
...
18 19 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.